Table 1.
Summary of animal numbers and mortality.
| Groups | Mortality | Excluded |
|---|---|---|
| Part 1: Time Course and Cellular Localization | ||
| Sham (n=8) | 0.0% (0/8) | 0 |
| SAH (3h, 6h, 12h, 24h, 72h) (n=32) | 12.5% (5/40) | 3 |
| Part 2: Study on the role of endogenous KISS1 after SAH | ||
| Sham (n=6) | 0.0% (0/6) | 0 |
| SAH (n=6) | 12.5% (1/8) | 1 |
| SAH + scrambled siRNA (n=6) | 12.5% (1/8) | 1 |
| SAH + KISS1 siRNA (n=6) | 33.3% (3/9) | 0 |
| Naïve + scrambled siRNA (n=4) | 0.0% (0/4) | 0 |
| Naïve + KISS1 siRNA (n=4) | 0.0% (0/4) | 0 |
| Part 3: Effects of KP54 on short-term outcome study | ||
| Sham (n=10) | 0.0% (0/10) | 0 |
| SAH + PBS (n=10) | 15.4% (2/13) | 1 |
| SAH + KP54 (0.1 nmol/kg) (n=6) | 22.2% (2/9) | 1 |
| SAH + KP54 (1.0 nmol/kg) (n=10) | 15.4% (2/13) | 1 |
| SAH + KP54 (10.0 nmol/kg) (n=6) | 33.3% (3/9) | 0 |
| Part 4: Effects of KP54 on long-term(28d) outcome study | ||
| Sham (n=10) | 0.0% (0/10) | 0 |
| SAH + PBS (n=10) | 33.3% (5/15) | 0 |
| SAH + KP54 (1.0 nmol/kg) (n=10) | 16.7% (2/12) | 0 |
| Part 5: Mechanism study of KP54/GPR54/ARRB2/AKT/GSK3β pathway after SAH | ||
| Sham (n=6) | 0.0% (0/6) | 0 |
| SAH + PBS (n=6) | 12.5% (1/8) | 1 |
| SAH + KP54 (1.0 nmol/kg) (n=6) | 14.3% (1/7) | 0 |
| SAH + KP54 + NS (n=6) | 12.5% (1/8) | 1 |
| SAH + KP54 + KP234 (n=6) | 25.0% (2/8) | 0 |
| SAH + KP54 + scrambled siRNA (n=6) | 0.0% (0/6) | 0 |
| SAH + KP54 + ARRB2 siRNA (n=6) | 14.3% (1/7) | 1 |
| Naïve + ARRB2 siRNA (n=4) | 0.0% (0/4) | 0 |
| Naïve + scrambled siRNA (n=4) | 0.0% (0/4) | 0 |
| SAH + ARRB2 siRNA (n=4) | 20.0% (1/5) | 0 |
| SAH + scrambled siRNA (n=4) | 0.0% (0/4) | 0 |
| Total | ||
| Naïve | 0.0% (0/16) | 0 |
| Sham | 0.0% (0/40) | 0 |
| SAH | 17.8% (34/191) | 11 |